跳至主要内容
临床试验/NCT00832806
NCT00832806已完成1 期

Smoking Cessation With Varenicline (Champix) and Integrated Voice Response Technology (IVR)

University of British Columbia1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
100
试验地点
1
主要终点
Self-reported continuous abstinence of smoking and exhaled carbon monoxide levels less than 10 ppm as measured and recorded by the research nurse at weeks 12 and 52.

研究概览

简要总结

The goal of this study is to provide you with an effective treatment for reducing the physical and emotional stress that can occur during the early phase of being without cigarettes. It is our hope that this treatment will help you to stay smoke-free. You will receive counseling and a supply of Champix, a medication to help suppress the symptoms of nicotine withdrawal.

Purpose: To assess the effect of extended Integrated Voice Response (IVR) on smoking cessation after varenicline (Champix) and IVR treatment Hypothesis: There will be significant increase in participants who do not smoke at 1 year if extended IVR is used after 12 weeks of varenicline (Champix) and IVR treatment.

详细描述

The automated IVR uses algorithms and sophisticated speech recognition (computerized) to engage smokers on the telephone; gather information, provide reinforcing messages and triage them to a study nurse for call-back within 2 working days if either the smoker or nurse identify help is required. The technology recognizes the smoker's verbal responses, documents them and thereby assists in guiding further follow-up. IVR is a low-cost, high-yield way of contacting smokers when they would not ordinarily be contacted.

When prospective subjects call to register, a voice message will ask them to leave their name, telephone number, and register their choice of session date they would like to attend (the telephone message will list the 3 choices of session dates - as outlined on the poster).

Each session is a combined Information, Screening, and Recruitment session, which will be held once a week at St. Paul's Hospital (for a period of 3 weeks). The sessions will begin with a presentation by the participating physician, and will be group-based. The sessions will include information about smoking, smoking cessation, varenicline (Champix), eligibility for the study, and the relevance of the questionnaire about demographics, motivation, stress, and smoking, and the consent form (see questionnaire attachment). (The consent forms will be distributed to the group so they may view them while their relevance is discussed). Potential subjects will be given an information package including the Canadian Cancer Society booklets "For Smokers Who Don't Want to Quit" and "For Smokers Who Want To Quit" (see booklet attachments in 9.8).

Potential subjects will then be asked to read the consent form. If they think they meet the inclusion and exclusion criteria and are interested in proceeding they will meet with the physician in private (in a conference room across the hall) after the session. The physician will determine their eligibility (as per inclusion and exclusion criteria). A Healthy Heart volunteer will then witness their signing of the consent form. They will be asked to sign a second consent form that will be marked "copy" and given to them.

There is no time limit to sign the consent form. If potential subjects would like to make an appointment with the study nurse to come in to sign the consent at a future date, they may do so. In this situation, the following study procedures would be completed at this later date.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Smoking 35 or more cigarettes per week or 5 or more cigarettes per day,
  • Smoking for at least 2 years, with no period of abstinence longer than 3 months.

排除标准

  • Using any smoking cessation drugs or nicotine replacement drugs in the last 3 months,
  • Use of medication to treat depression or any psychiatric illness,
  • Impaired renal function,
  • Unstable medical condition,
  • Pregnancy or breast feeding.

研究组 & 干预措施

1

Active Comparator

Extended IVR (integrated voice response technology) vs. no extended IVR

干预措施: Extended IVR (integrated voice response technology) (Behavioral)

1

Active Comparator

Extended IVR (integrated voice response technology) vs. no extended IVR

干预措施: Varenicline (Champix) (Drug)

1

Active Comparator

Extended IVR (integrated voice response technology) vs. no extended IVR

干预措施: IVR treatment (Behavioral)

2

Active Comparator

Extended IVR (integrated voice response technology) vs. no extended IVR

干预措施: Varenicline (Champix) (Drug)

2

Active Comparator

Extended IVR (integrated voice response technology) vs. no extended IVR

干预措施: IVR treatment (Behavioral)

结局指标

主要结局

Self-reported continuous abstinence of smoking and exhaled carbon monoxide levels less than 10 ppm as measured and recorded by the research nurse at weeks 12 and 52.

时间窗: 1 year

次要结局

  • Self-reported date of smoking and number of cigarettes smoked from weeks 13 to 52.(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验